Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002)
NCT01749540
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
64
Enrollment
INDUSTRY
Sponsor class
Conditions
B-Thalassemia
Interventions
DRUG:
luspatercept
Sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA